Genetic Signatures (GSS) H1 2026 earnings summary

Executive summary

• Revenue reached $8.7 million for 1H FY26, up from $8.5 million in 1H FY25, driven by steady Australian sales and growth in the US and EMEA, particularly from respiratory and gastroenteric testing.

• Gross profit declined to $4.8 million, with gross margin down to 55.7% from 58.8%, impacted by higher consumables and raw material costs, especially for respiratory kits.

• Net loss improved to $6.4 million from $8.4 million (or $15.2 million including prior non-recurring impairment), aided by R&D tax incentive income and cost reductions.

• Cash and cash equivalents stood at $29.9 million at 31 December 2025, with cash burn of approximately $7 million in the half and improved working capital.

• Leadership transition underway, with Maria Halasz appointed CEO effective March 2026, Anne Lockwood as Interim Managing Director, and Dr Susanne Pedersen as CTO.

Financial highlights

• Revenue of $8.7 million, up from $8.5 million in 1H FY25, with growth in the US and EMEA and steady Australian sales.

• Gross profit margin declined to 55.7% from 58.8% due to increased consumable and raw material costs.

• Net loss improved to $6.4 million, with other income boosted by a $4.4 million R&D Tax Incentive.

• Cash used in operations was $5.2 million; capex of $0.6 million focused on R&D and equipment.

• Net assets declined to $44.1 million at 31 December 2025.

Outlook and guidance

• Focus on strengthening the Australian market and accelerating global expansion, especially in the US and EMEA.

• Board and advisors are reviewing operational and financial performance to streamline costs and maximize shareholder value, with savings expected over FY27.

• Ongoing development of next-generation instruments and automation to meet market needs.

• No formal guidance figures provided; cost discipline and international growth remain strategic priorities.